Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
6.05
-0.24 (-3.82%)
At close: Jun 8, 2026, 4:00 PM EDT
6.05
0.00 (0.00%)
After-hours: Jun 8, 2026, 4:10 PM EDT
Gyre Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 49.81 | 52.43 | 26.67 | 33.51 | 25.18 | 44.35 |
Short-Term Investments | - | - | - | - | - | 2.5 |
Cash & Short-Term Investments | 49.81 | 52.43 | 26.67 | 33.51 | 25.18 | 46.85 |
Cash Growth | 66.63% | 96.56% | -20.41% | 33.10% | -46.27% | -40.96% |
Accounts Receivable | 22.76 | 31.08 | 19.59 | 15.16 | 17.14 | 1.82 |
Other Receivables | 4.05 | 5.87 | 9.56 | 1.68 | - | - |
Total Trade Receivables | 26.81 | 36.95 | 29.15 | 16.84 | 17.14 | 1.82 |
Inventory | - | - | - | 4.28 | 6.12 | - |
Other Current Assets | 3.76 | 2.83 | 2.63 | 2.59 | 1.22 | 2.81 |
Total Current Assets | 91.73 | 102.37 | 64.79 | 57.22 | 49.65 | 51.48 |
Net Property, Plant & Equipment | 23.57 | 24.73 | 25.7 | 23.76 | 18.38 | 3.71 |
Other Intangible Assets | 4.63 | 4.73 | 0.27 | 0.21 | 0.3 | - |
Other Long-Term Assets | 42.08 | 34.31 | 34.65 | 11.91 | 16.43 | 0.47 |
Total Assets | 162.02 | 166.13 | 125.41 | 116.54 | 84.75 | 55.66 |
Accounts Payable | 0.27 | 0.12 | 0.11 | 0.36 | 0.12 | 6.42 |
Accrued Expenses | 15.42 | 14.35 | 10.62 | 11.94 | 9.26 | 5.54 |
Current Portion of Leases | 0.75 | 0.64 | 0.71 | 0.21 | 0.49 | 1.98 |
Unearned Revenue | - | 0.01 | 0.06 | 0.04 | 0.15 | 0.23 |
Other Current Liabilities | 3.36 | 3.17 | 8.02 | 7.51 | 2.22 | - |
Total Current Liabilities | 19.79 | 18.29 | 19.52 | 20.05 | 12.24 | 14.17 |
Long-Term Leases | 0.07 | 0.3 | 0.89 | 0.2 | 0.12 | 0.41 |
Other Long-Term Liabilities | 5.17 | 5.26 | 6.6 | 17.82 | 0.17 | - |
Total Long-Term Liabilities | 5.24 | 5.56 | 7.49 | 18.02 | 0.29 | 0.41 |
Total Liabilities | 25.03 | 23.85 | 27 | 38.07 | 12.54 | 14.57 |
Common Stock | 0.09 | 0.09 | 0.09 | 0.08 | 0.06 | 0.03 |
Additional Paid-in Capital | 174.65 | 172.05 | 136.19 | 68.18 | 32.8 | 443.75 |
Accumulated Other Comprehensive Income | 0.59 | -0.78 | -2.6 | -1.64 | -0.39 | - |
Retained Earnings | -74.02 | -65.33 | -70.36 | -82.44 | 10.06 | -402.69 |
Total Common Shareholders' Equity | 101.31 | 106.03 | 63.32 | -15.83 | 42.52 | 41.09 |
Minority Interest | 35.68 | 36.25 | 35.08 | 94.3 | 29.7 | - |
Shareholders' Equity | 136.99 | 142.28 | 98.4 | 13.95 | 72.22 | 41.09 |
Total Liabilities & Equity | 162.02 | 166.13 | 125.41 | 116.54 | 84.75 | 55.66 |
Total Debt | 0.82 | 0.94 | 1.6 | 0.41 | 0.61 | 2.39 |
Net Cash (Debt) | 48.99 | 51.49 | 25.07 | 33.1 | 24.56 | 44.47 |
Net Cash Growth | -4.86% | 105.34% | -24.25% | 34.76% | -44.76% | -42.78% |
Net Cash Per Share | 0.50 | 0.50 | 0.24 | 0.50 | 0.33 | 0.67 |
Book Value | 101.31 | 106.03 | 63.32 | -15.83 | 42.52 | 41.09 |
Book Value Per Share | 1.04 | 1.03 | 0.62 | -0.24 | 0.56 | 0.62 |
Tangible Book Value | 96.68 | 101.3 | 63.05 | -16.03 | 42.23 | 41.09 |
Tangible Book Value Per Share | 0.99 | 0.98 | 0.62 | -0.24 | 0.56 | 0.62 |